Baxter acquires ex US and ex Taiwan rights to MM 398 from Merrimack Pharma for Pancreatic and other cancers.

Baxter International Inc. and Merrimack Pharmaceuticals, Inc. jointly announced an exclusive license and collaboration agreement for the development and commercialization of MM-398 (nanoliposomal irinotecan injection), also known as 'nal-IRI.' Through the agreement, Baxter gains exclusive commercialization rights for all potential indications of MM-398 outside the United States and Taiwan , and Merrimack retains commercialization rights in the United States ; the rights in Taiwan are held separately.

MM-398 is an investigational drug candidate for which Merrimack is preparing a New Drug Application in the United States for the treatment of patients with metastatic pancreatic cancer previously treated with a gemcitabine-based therapy. Pancreatic cancer is a rare and deadly disease that is difficult to diagnose and has limited treatment options available today.